Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nippon Shinyaku Licenses Prulifloxacin Marketing Rights To Lee’s Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

Kyoto-based Nippon Shinyaku announced March 3 a licensing agreement on antibacterial drug prulifloxacin with Hong Kong biopharmaceutical company Lee's Pharmaceutical Holdings, which gives Lee's the exclusive marketing rights in China for antibacterial drugs containing prulifloxacin. Nippon Shinyaku will receive an undisclosed upfront payment, milestone payments based on sales achievement and product royalties. An oral broad spectrum fluoroquinolone antibiotic developed by Nippon Shinyaku, prulifloxacin is marketed in Japan by Meiji Seika with the name Sword and by Angelini with the name Unidrox in Europe. (Click here for more - Japanese language
Advertisement

Related Content

One Drug Outfit On China's Periphery Stands Out From The Crowd Through Innovation
Advertisement
UsernamePublicRestriction

Register

SC071268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel